226 related articles for article (PubMed ID: 17303370)
1. [Multidisciplinary consultation for the prescription of danaparoid in suspected heparin-induced thrombocytopenia].
Verdy E; Debrix I; Benomar A; Becker A; Flahault A
Presse Med; 2007 May; 36(5 Pt 1):786-93. PubMed ID: 17303370
[TBL] [Abstract][Full Text] [Related]
2. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
Magnani HN; Gallus A
Thromb Haemost; 2006 Jun; 95(6):967-81. PubMed ID: 16732376
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
Tardy-Poncet B; Tardy B; Reynaud J; Mahul P; Mismetti P; Mazet E; Guyotat D
Chest; 1999 Jun; 115(6):1616-20. PubMed ID: 10378558
[TBL] [Abstract][Full Text] [Related]
4. The management of heparin-induced thrombocytopenia.
Keeling D; Davidson S; Watson H;
Br J Haematol; 2006 May; 133(3):259-69. PubMed ID: 16643427
[TBL] [Abstract][Full Text] [Related]
5. [Thrombocytopenia due to heparin therapy. Use of danaparoid (Orgaran), 13 monocentric cases under authorization of temporary prescription (ATU)].
Gindre L; de Maistre E; Perrin A; Lecompte T; Hoffman MA
Therapie; 1997; 52(6):591-7. PubMed ID: 9734113
[TBL] [Abstract][Full Text] [Related]
6. Persistent heparin-induced thrombocytopenia: danaparoid cross-reactivity or delayed-onset heparin-induced thrombocytopenia? A case report.
Horlait G; Minet V; Mullier F; Michaux I
Blood Coagul Fibrinolysis; 2017 Mar; 28(2):193-197. PubMed ID: 27100305
[TBL] [Abstract][Full Text] [Related]
7. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.
Schenk JF; Pindur G; Stephan B; Mörsdorf S; Mertzlufft F; Kroll H; Wenzel E; Seyfert UT
Clin Appl Thromb Hemost; 2003 Jan; 9(1):25-32. PubMed ID: 12643320
[TBL] [Abstract][Full Text] [Related]
8. [Clinical experiences with Danaparoid sodium. Measures to be taken in heparin-induced thrombocytopenia].
Anaesthesist; 1998 Nov; 47(11 Suppl Massnahmen):1-4. PubMed ID: 9884734
[No Abstract] [Full Text] [Related]
9. Risk factors for unfavorable clinical outcome in patients with documented heparin-induced thrombocytopenia.
Elalamy I; Tardy-Poncet B; Mulot A; de Maistre E; Pouplard C; Nguyen P; Cleret B; Gruel Y; Lecompte T; Tardy B;
Thromb Res; 2009 Nov; 124(5):554-9. PubMed ID: 19410277
[TBL] [Abstract][Full Text] [Related]
10. [Heparin-induced thrombocytopenia].
Christoffersen C; Lethagen S; Gøtze JP
Ugeskr Laeger; 2009 Feb; 171(8):612-5. PubMed ID: 19284907
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulative management of patients requiring left ventricular assist device implantation and suffering from heparin-induced thrombocytopenia type II.
Christiansen S; Jahn UR; Meyer J; Scheld HH; Van Aken H; Kehrel BE; Hammel D
Ann Thorac Surg; 2000 Mar; 69(3):774-7. PubMed ID: 10750760
[TBL] [Abstract][Full Text] [Related]
12. [Danaparoid in pregnancy in cases of heparin intolerance - use in 59 cases].
Schindewolf M; Magnani HN; Lindhoff-Last E
Hamostaseologie; 2007 May; 27(2):89-97. PubMed ID: 17479171
[TBL] [Abstract][Full Text] [Related]
13. Cross-Reactivity Between Heparin and Danaparoid Antibodies in Cardiac Surgery.
Ronchard T; Salaun E; Theron A; Grisoli D; Jaussaud N; Collart F; Habib G; Camoin-Jau L
Ann Thorac Surg; 2017 Jan; 103(1):e9-e10. PubMed ID: 28007287
[TBL] [Abstract][Full Text] [Related]
14. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s.
Lubenow N; Warkentin TE; Greinacher A; Wessel A; Sloane DA; Krahn EL; Magnani HN
Thromb Res; 2006; 117(5):507-15. PubMed ID: 15907979
[TBL] [Abstract][Full Text] [Related]
15. Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium.
Ranze O; Ranze P; Magnani HN; Greinacher A
Eur J Pediatr; 1999 Dec; 158 Suppl 3():S130-3. PubMed ID: 10650852
[TBL] [Abstract][Full Text] [Related]
16. [Clinical experience with Danaparoid-sodium: measures to be taken in heparin-induced thrombocytopenia].
Chirurg; 1998 Nov; 69(11 Suppl Massnahme):1-4. PubMed ID: 9853175
[No Abstract] [Full Text] [Related]
17. Heparin-induced thrombocytopenia: a ten-year retrospective.
Warkentin TE
Annu Rev Med; 1999; 50():129-47. PubMed ID: 10073268
[TBL] [Abstract][Full Text] [Related]
18. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
Wilde MI; Markham A
Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
[TBL] [Abstract][Full Text] [Related]
19. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation.
Lindhoff-Last E; Bauersachs R
Semin Thromb Hemost; 2002 Oct; 28(5):439-46. PubMed ID: 12420239
[TBL] [Abstract][Full Text] [Related]
20. [Heparin-induced thrombopenia].
de Maistre E; Wahl D; Briquel ME; André E; Lecompte T
Ann Cardiol Angeiol (Paris); 1999 Jan; 48(1):37-41. PubMed ID: 12555357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
